Publicaciones en las que colabora con SILVIA ORTEGA GUTIÉRREZ (23)

2021

  1. Chemistry for the Identification of Therapeutic Targets: Recent Advances and Future Directions

    European Journal of Organic Chemistry, Vol. 2021, Núm. 9, pp. 1307-1320

  2. Isoprenylcysteine Carboxylmethyltransferase-Based Therapy for Hutchinson-Gilford Progeria Syndrome

    ACS Central Science, Vol. 7, Núm. 8, pp. 1300-1310

  3. Small-molecule therapeutic perspectives for the treatment of progeria

    International Journal of Molecular Sciences, Vol. 22, Núm. 13

2019

  1. A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia

    Journal of Medicinal Chemistry, Vol. 62, Núm. 13, pp. 6035-6046

  2. Astroglial monoacylglycerol lipase controls mutant huntingtin-induced damage of striatal neurons

    Neuropharmacology, Vol. 150, pp. 134-144

2018

  1. Development of a Fluorescent Bodipy Probe for Visualization of the Serotonin 5-HT 1A Receptor in Native Cells of the Immune System

    Bioconjugate Chemistry, Vol. 29, Núm. 6, pp. 2021-2027

  2. A Fluorescent Probe to Unravel Functional Features of Cannabinoid Receptor CB1 in Human Blood and Tonsil Immune System Cells

    Bioconjugate Chemistry, Vol. 29, Núm. 2, pp. 382-389

2016

  1. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

    Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400

2015

  1. New inhibitors of angiogenesis with antitumor activity in vivo

    Journal of Medicinal Chemistry, Vol. 58, Núm. 9, pp. 3757-3766

  2. Role of cannabinoid receptor CB<inf>2</inf> in HER2 pro-oncogenic signaling in breast cancer

    Journal of the National Cancer Institute, Vol. 107, Núm. 6

2014

  1. The expression of cannabinoid receptor 1 is significantly increased in atopic patients

    Journal of Allergy and Clinical Immunology, Vol. 133, Núm. 3

2013

  1. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system

    International Journal of Neuropsychopharmacology, Vol. 16, Núm. 6, pp. 1407-1419

2007

  1. Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions

    Life Sciences, Vol. 80, Núm. 10, pp. 979-988

2006

  1. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders

    European Neuropsychopharmacology, Vol. 16, Núm. 1, pp. 7-18

2005

  1. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels

    Biochemical Pharmacology, Vol. 70, Núm. 3, pp. 446-452

2004

  1. Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: Synthesis of new transporter inhibitors as tools for this study

    British Journal of Pharmacology, Vol. 141, Núm. 3, pp. 457-467

2003

  1. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors

    European Journal of Medicinal Chemistry

  2. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects on fatty acid amidohydrolase

    Journal of Medicinal Chemistry, Vol. 46, Núm. 8, pp. 1512-1522

  3. Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 18, Núm. 3, pp. 225-231

2002

  1. Endocannabinoid transporter inhibitors

    Current Medicinal Chemistry - Central Nervous System Agents, Vol. 2, Núm. 2, pp. 129-141